Shortening Overall Treatment to 12 Weeks of SIMEPREVIR Plus Pegylated-Interferon/ribavirin According to Early Virologic Response in Treatment-Naïve Patients with Chronic HCV Genotype 4 Infection and Mild-to-moderate Fibrosis

Aims: HCV genotype 4 (GT4) is highly prevalent in the Middle East and Sub-Saharan Africa, and is expanding in Europe. To prevent disease progression, short and effective regimens are needed for these patients. This study aims to assess whether treatment with simeprevir+Peg-IFN/ribavirin can be shortened to 12 weeks, based on early viral kinetics, in patients with mild-to-moderate fibrosis.